• Hyperuricemia

Elitek Generic Name & Formulations

General Description

Rasburicase (recombinant) 1.5mg, 7.5mg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution; contains mannitol.

Pharmacological Class

Urate oxidase.

How Supplied

Single-dose vials 1.5mg—3 (w. diluent); 7.5mg—1 (w. diluent)


Generic Availability


Elitek Indications


Single course treatment for initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.

Elitek Dosage and Administration

Adults and Children

Give by IV infusion over 30 mins. 0.2mg/kg daily for 5 days. Dosing >5 days or more than one course of treatment: not recommended.

Elitek Contraindications


History of anaphylaxis, or development of hemolytic reactions or methemoglobinemia to rasburicase. G6PD deficiency.

Elitek Boxed Warnings

Boxed Warning

Anaphylaxis. Hemolysis. Methemoglobinemia. Interference with uric acid measurements.

Elitek Warnings/Precautions


Discontinue permanently if serious hypersensitivity reactions (including anaphylaxis), hemolysis, or methemoglobinemia develops. Screen high risk patients (eg, African or Mediterranean ancestry) for G6PD deficiency prior to initiation. Pregnancy. Nursing mothers: not recommended (during and for 2 weeks after the last dose).

Elitek Pharmacokinetics

See Literature

Elitek Interactions


Interferes with uric acid measurements in blood samples left at room temperature.

Elitek Adverse Reactions

Adverse Reactions

GI upset, pyrexia, peripheral edema, anxiety, headache, abdominal pain, constipation, hypophosphatemia, hyperbilirubinemia, mucositis, sepsis; anaphylaxis, hemolysis, methemoglobinemia.

Elitek Clinical Trials

See Literature

Elitek Note

Not Applicable

Elitek Patient Counseling

See Literature